Identification and validation of five novel protein targets for type 2 diabetes mellitus

鉴定和验证2型糖尿病的五个新型蛋白质靶点

阅读:1

Abstract

Despite advances in type 2 diabetes mellitus (T2DM) therapy, challenges remain due to the lack of novel therapeutic targets. We used Mendelian randomization to integrate cis-expression quantitative trait loci data for circulating proteins from the eQTLGen Consortium (31,684 individuals) with T2DM summary statistics from the Integrative Epidemiology Unit Open Genome-Wide Association Studies Project (61,714 cases, 593,952 controls). 42 genes were significantly associated with T2DM. Colocalization analysis revealed that six genes (CLSTN1, KCNJ11, MLX, DLD, RELA, and ULK1) shared common causal variants with T2DM. Among them, CLSTN1 (OR = 0.80, 95% CI: 0.70-0.90), KCNJ11 (OR = 0.66, 95% CI: 0.60-0.73), and MLX (OR = 0.73, 95% CI: 0.65-0.82) were negatively associated with T2DM, while DLD (OR = 1.38, 95% CI: 1.15-1.65), RELA (OR = 1.90, 95% CI: 1.41-2.55), and ULK1 (OR = 1.42, 95% CI: 1.17-1.71) were positively associated with T2DM. A matched case-control study further validated these associations, except for DLD, showing significant downregulation of CLSTN1, KCNJ11, and MLX (P < 0.05) alongside upregulation of RELA and ULK1 (P < 0.05) in T2DM patients. These findings underscore the potential of these proteins as drug targets, warranting further clinical investigation to confirm their therapeutic relevance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。